Table 3 Univariate and multivariate analysis for overall survival and disease -free survival in the matched cohort

Age(years)

 ≤ 65

 > 65

1.517(1.096–2.101)

1.388(0.993–1.938)

1.394(1.029–1.890)

1.233(0.890–1.708)

Sex

 Female

 Male

0.967(0.701–1.334)

0.854(0.633–1.151)

BMI (kg/m2)

 ≤ 18.5

 18.5–25

1.148(0.703–1.874)

1.316(0.819–2.115)

 ≥ 25

1.277(0.712–2.291)

1.585(0.913–2.751)

Tumor location

 Proximal

 Mid

1.281(0.737–2.226)

1.479(0.870–2.514)

 Distal

1.347(0.747–2.431)

1.442(0.819–2.539)

Histologic grade

 Gx/G1

 G2

1.166(0.855–1.589)

1.227(0.891–1.690)

1.145(0.865–1.516)

 G3

1.623(1.058–2.491)

1.414(0.915–2.185)

1.344(0.895–2.018)

T stage

 T1

 T2

2.172(1.189–3.970)

1.661(0.894–3.084)

1.928(1.157–3.213)

1.523(0.895–2.592)

 T3/T4a

4.492(2.717–7.428)

2.832(1.657–4.843)

3.552(2.332–5.411)

2.399(1.513–3.804)

N stage

 N0

 N1

2.372(1.639–3.431)

2.071(1.414–3.033)

2.045(1.463–2.859)

1.828(1.282–2.607)

 N2/3

3.864(2.745–5.438)

3.097(2.135–4.492)

3.523(2.591–4.791)

2.947(2.103–4.131)

Surgical procedure

 McKeown

 Ivor Lewis

0.686(0.422–1.116)

0.772(0.505–1.179)

Lymphadenectomy

 Two-field

 Three-field

0.969(0.620–1.513)

0.898(0.587–1.375)

Intraoperative bleeding(ml)

 ≤ 100

 100–200

1.199(0.878–1.637)

1.154(0.842–1.581)

1.118(0.837–1.492)

1.151(0.861–1.540)

 ≥ 200

2.106(1.382–3.209)

2.244(1.452–3.469)

2.241(1.544–3.253)

2.398(1.631–3.526)

Clavien–Dindo grade

 < II

 ≥ II

1.679(1.261–2.235)

1.373(1.026–1.837)

1.617(1.245–2.101)

1.320(1.008–1.728)

Adjuvant chemotherapy

 No

 Yes

1.294(0.970–1.726)

1.348(1.036–1.756)

0.873(0.650–1.173)

LDH(IU/L)

 Mean ± SD

1.004(1.001–1.007)

1.003(1.000–1.006)

1.003(1.001–1.006)

1.002(0.999–1.005)

dNLR

 Mean ± SD

1.138(1.021–1.268)

0.913(0.775–1.076)

1.107(0.998–1.228)

IPI group

 Low

 High

2.020(1.495–2.731)

1.886(1.323–2.689)

1.785(1.362–2.340)

1.500(1.121–2.009)